MA38170A1 - Nouveaux acides indanyloxydihydrobenzofuranylacétiques - Google Patents
Nouveaux acides indanyloxydihydrobenzofuranylacétiquesInfo
- Publication number
- MA38170A1 MA38170A1 MA38170A MA38170A MA38170A1 MA 38170 A1 MA38170 A1 MA 38170A1 MA 38170 A MA38170 A MA 38170A MA 38170 A MA38170 A MA 38170A MA 38170 A1 MA38170 A1 MA 38170A1
- Authority
- MA
- Morocco
- Prior art keywords
- new
- indanyloxydihydrobenzofuranylacetic acids
- receptor
- acids
- new indanyloxydihydrobenzofuranylacetic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/80—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Furan Compounds (AREA)
Abstract
La présente invention porte sur des composés représentés par la formule générale (i), dans laquelle le groupe (het)ar est tel que défini dans la revendication 1, qui ont des propriétés pharmacologiques de valeur, en particulier qui se lient au récepteur gpr40 et modulent son activité. Les composés sont appropriés pour le traitement et la prévention de maladies qui peuvent être influencées par ce récepteur, telles que des maladies métaboliques, en particulier le diabète de type 2.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12194590 | 2012-11-28 | ||
PCT/EP2013/074386 WO2014082918A1 (fr) | 2012-11-28 | 2013-11-21 | Nouveaux acides indanyloxydihydrobenzofuranylacétiques |
Publications (2)
Publication Number | Publication Date |
---|---|
MA38170A1 true MA38170A1 (fr) | 2016-09-30 |
MA38170B1 MA38170B1 (fr) | 2017-04-28 |
Family
ID=47257634
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA38170A MA38170B1 (fr) | 2012-11-28 | 2013-11-21 | Nouveaux acides indanyloxydihydrobenzofuranylacétiques |
Country Status (23)
Country | Link |
---|---|
US (1) | US8815864B2 (fr) |
EP (1) | EP2925748B1 (fr) |
JP (1) | JP5913752B2 (fr) |
KR (1) | KR20150088878A (fr) |
CN (1) | CN104822675A (fr) |
AP (1) | AP2015008364A0 (fr) |
AR (1) | AR093631A1 (fr) |
AU (1) | AU2013351377A1 (fr) |
BR (1) | BR112015009376A2 (fr) |
CA (1) | CA2889783A1 (fr) |
CL (1) | CL2015001256A1 (fr) |
EA (1) | EA201500574A1 (fr) |
HK (1) | HK1210144A1 (fr) |
IL (1) | IL238128A0 (fr) |
MA (1) | MA38170B1 (fr) |
MX (1) | MX2015006591A (fr) |
PE (1) | PE20150968A1 (fr) |
PH (1) | PH12015501116A1 (fr) |
SG (1) | SG11201503800QA (fr) |
TN (1) | TN2015000158A1 (fr) |
TW (1) | TW201439075A (fr) |
UY (1) | UY35156A (fr) |
WO (1) | WO2014082918A1 (fr) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2928886B1 (fr) | 2012-12-07 | 2016-11-02 | Boehringer Ingelheim International GmbH | Nouveaux acides indanyloxydihydrobenzofuranylacétiques |
ES2739433T3 (es) * | 2013-09-09 | 2020-01-31 | Peloton Therapeutics Inc | Aril éteres y usos de los mismos |
KR20160077213A (ko) | 2013-11-14 | 2016-07-01 | 카딜라 핼쓰캐어 리미티드 | 새로운 헤테로시클릭 화합물 |
ES2737148T3 (es) | 2013-12-16 | 2020-01-10 | Peloton Therapeutics Inc | Análogos de sulfona y sulfoximina cíclicos y usos de los mismos |
TW201613878A (en) | 2014-07-09 | 2016-04-16 | Janssen Pharmaceutica Nv | Pyrazine GPR40 agonists for the treatment of type II diabetes |
WO2016144825A1 (fr) | 2015-03-11 | 2016-09-15 | Peloton Therapeutics, Inc. | Composés aromatiques, leurs et utilisations |
EP3268362B1 (fr) | 2015-03-11 | 2021-10-20 | Peloton Therapeutics, Inc. | Pyridines substituées et leurs utilisations |
EP3267792A4 (fr) | 2015-03-11 | 2018-09-26 | Peloton Therapeutics, Inc. | Compositions utilisées pour traiter l'hypertension artérielle pulmonaire |
WO2016145045A1 (fr) | 2015-03-11 | 2016-09-15 | Peloton Therapeutics, Inc. | Compositions s'utilisant dans le traitement du glioblastome |
US10335388B2 (en) | 2015-04-17 | 2019-07-02 | Peloton Therapeutics, Inc. | Combination therapy of a HIF-2-alpha inhibitor and an immunotherapeutic agent and uses thereof |
EP3573969A1 (fr) | 2017-01-26 | 2019-12-04 | Boehringer Ingelheim International GmbH | Acides benzyloxypyrazinylcyclopropanecarboxyliques, compositions pharmaceutiques et utilisations associées |
JP7049349B2 (ja) | 2017-01-26 | 2022-04-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ベンジルアミノピラジニルシクロプロパンカルボン酸、その医薬組成物及び使用 |
EP3573952B1 (fr) | 2017-01-26 | 2021-07-14 | Boehringer Ingelheim International GmbH | Acides benzylaminopyridylcyclopropanecarboxyliques, compositions pharmaceutiques et utilisations associées |
JP7050791B2 (ja) | 2017-01-26 | 2022-04-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ベンジルオキシピリジルシクロプロパンカルボン酸、その医薬組成物及び使用 |
CN110300755B (zh) * | 2017-02-08 | 2022-10-04 | 勃林格殷格翰国际有限公司 | 茚满基氨基氮杂二氢苯并呋喃乙酸、用于治疗糖尿病的药物组合物 |
AU2019222644B2 (en) | 2018-02-13 | 2021-04-01 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
US10899735B2 (en) | 2018-04-19 | 2021-01-26 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
JP7105359B2 (ja) | 2018-07-13 | 2022-07-22 | ギリアード サイエンシーズ, インコーポレイテッド | Pd-1/pd-l1阻害剤 |
AU2019366355B2 (en) | 2018-10-24 | 2022-10-13 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
WO2021071837A1 (fr) | 2019-10-07 | 2021-04-15 | Kallyope, Inc. | Agonistes de gpr119 |
UY39222A (es) | 2020-05-19 | 2021-11-30 | Kallyope Inc | Activadores de la ampk |
CA3183575A1 (fr) | 2020-06-26 | 2021-12-30 | Iyassu Sebhat | Activateurs d'ampk |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003277576A1 (en) | 2002-11-08 | 2004-06-07 | Takeda Pharmaceutical Company Limited | Receptor function controlling agent |
US7582803B2 (en) | 2005-09-14 | 2009-09-01 | Amgen Inc. | Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders |
EP2431367A3 (fr) | 2006-06-27 | 2012-07-04 | Takeda Pharmaceutical Company Limited | Composés cycliques condensés comme modulateurs du recepteur GPR40 |
AU2009263384A1 (en) | 2008-06-25 | 2009-12-30 | Daiichi Sankyo Company, Limited | Carboxylic acid compound |
US20120302566A1 (en) | 2010-12-01 | 2012-11-29 | Boehringer Ingelheim International Gmbh | Indanyloxydihydrobenzofuranylacetic acids |
-
2013
- 2013-11-21 AP AP2015008364A patent/AP2015008364A0/xx unknown
- 2013-11-21 EA EA201500574A patent/EA201500574A1/ru unknown
- 2013-11-21 BR BR112015009376A patent/BR112015009376A2/pt not_active IP Right Cessation
- 2013-11-21 PE PE2015000689A patent/PE20150968A1/es not_active Application Discontinuation
- 2013-11-21 EP EP13794906.1A patent/EP2925748B1/fr active Active
- 2013-11-21 MA MA38170A patent/MA38170B1/fr unknown
- 2013-11-21 MX MX2015006591A patent/MX2015006591A/es unknown
- 2013-11-21 SG SG11201503800QA patent/SG11201503800QA/en unknown
- 2013-11-21 AU AU2013351377A patent/AU2013351377A1/en not_active Abandoned
- 2013-11-21 WO PCT/EP2013/074386 patent/WO2014082918A1/fr active Application Filing
- 2013-11-21 CN CN201380062232.3A patent/CN104822675A/zh active Pending
- 2013-11-21 CA CA2889783A patent/CA2889783A1/fr not_active Abandoned
- 2013-11-21 JP JP2015543427A patent/JP5913752B2/ja active Active
- 2013-11-21 KR KR1020157017075A patent/KR20150088878A/ko not_active Application Discontinuation
- 2013-11-25 US US14/088,493 patent/US8815864B2/en active Active
- 2013-11-27 AR ARP130104372A patent/AR093631A1/es unknown
- 2013-11-27 TW TW102143328A patent/TW201439075A/zh unknown
- 2013-11-28 UY UY0001035156A patent/UY35156A/es unknown
-
2015
- 2015-04-02 IL IL238128A patent/IL238128A0/en unknown
- 2015-04-24 TN TNP2015000158A patent/TN2015000158A1/fr unknown
- 2015-05-11 CL CL2015001256A patent/CL2015001256A1/es unknown
- 2015-05-20 PH PH12015501116A patent/PH12015501116A1/en unknown
- 2015-11-03 HK HK15110811.9A patent/HK1210144A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
SG11201503800QA (en) | 2015-06-29 |
EA201500574A1 (ru) | 2015-11-30 |
JP2016500089A (ja) | 2016-01-07 |
MA38170B1 (fr) | 2017-04-28 |
AP2015008364A0 (en) | 2015-04-30 |
JP5913752B2 (ja) | 2016-04-27 |
AR093631A1 (es) | 2015-06-17 |
UY35156A (es) | 2014-05-30 |
BR112015009376A2 (pt) | 2017-07-04 |
WO2014082918A1 (fr) | 2014-06-05 |
CA2889783A1 (fr) | 2014-06-05 |
EP2925748A1 (fr) | 2015-10-07 |
PH12015501116A1 (en) | 2015-08-10 |
US8815864B2 (en) | 2014-08-26 |
MX2015006591A (es) | 2015-08-05 |
CL2015001256A1 (es) | 2015-07-24 |
PE20150968A1 (es) | 2015-07-09 |
US20140148462A1 (en) | 2014-05-29 |
KR20150088878A (ko) | 2015-08-03 |
TW201439075A (zh) | 2014-10-16 |
AU2013351377A1 (en) | 2015-04-16 |
EP2925748B1 (fr) | 2017-01-11 |
TN2015000158A1 (en) | 2016-10-03 |
HK1210144A1 (en) | 2016-04-15 |
IL238128A0 (en) | 2015-05-31 |
CN104822675A (zh) | 2015-08-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA38170A1 (fr) | Nouveaux acides indanyloxydihydrobenzofuranylacétiques | |
MA20150065A1 (fr) | Nouveaux dérivés d'acide indanyloxydihydrobenzofurannylacétique et leur utilisation comme agonistes du récepteur gpr40 | |
EA201070535A1 (ru) | Новые агонисты глюкокортикоидных рецепторов | |
MA34383B1 (fr) | Analogues de glucagon | |
MA34916B1 (fr) | Nouveaux dérivés d'azabenzimidazole cyclique utiles en tant qu'agents antidiabétiques | |
MA41562B1 (fr) | Agonistes d'apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculaires | |
MA34839B1 (fr) | Dihydrofuranes condensés en tant que modulateurs de gpr119 pour le traitement du diabète, de l'obésité et de troubles apparentes | |
MA34361B1 (fr) | Dérivés de tétrahydro-pyrido-pyrimidine | |
MA33428B1 (fr) | Agonistes du gpr119 | |
MA37983A1 (fr) | Analogues du glucagon | |
TN2009000324A1 (fr) | Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoides | |
MA30228B1 (fr) | Pipéridinoylpyrrolidines agonistes du récepteur de mélanocortine de type 4 | |
EA201171098A1 (ru) | 8-замещенные хинолины и родственные аналоги в качестве модуляторов сиртуина | |
EA200602242A1 (ru) | 3-аминоциклопентанкарбоксамиды в качестве модуляторов хемокиновых рецепторов | |
EA201190207A1 (ru) | Соединения для лечения метаболических расстройств | |
MA33242B1 (fr) | Composes pour le traitement de troubles metaboliques | |
EA200602243A1 (ru) | 3-аминоциклопентанкарбоксамиды в качестве модуляторов хемокиновых рецепторов | |
EA201190004A1 (ru) | Конденсированные имидазол карбоксамиды в качестве модуляторов trpv3 | |
EA201491213A1 (ru) | Антагонисты trpm8 | |
EA201390826A1 (ru) | ПИРИМИДИНОНОВЫЕ СОЕДИНЕНИЯ ДЛЯ ПРИМЕНЕНИЯ В ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ ИЛИ СОСТОЯНИЙ, ОПОСРЕДОВАННЫХ Lp-PLA | |
FR2981934B1 (fr) | Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines. | |
DE602006019911D1 (de) | Mglur1-antagonisten als therapeutische wirkstoffe | |
MA34175B1 (fr) | Anticorps anti-cxcr4 humanisés pour le traitement de cancer | |
EA200900330A1 (ru) | Аналоги 2-феноксипиримидинона | |
MA38217B1 (fr) | Nouveaux dérivés de pyrazine comme agonistes des récepteurs cb2 |